Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2Pseudomonas Infections 1Pneumonia 1Neutropenia 1Neoplasms 1Gram-Negative Bacterial Infections 1Bacteremia 1

Interventions

Filgrastim 7pegylated granulocyte colony-stimulating factor 5pegfilgrastim 5Cytarabine 4Ciprofloxacin 4Cefepime 4Vancomycin 3Leucovorin 3Fluorouracil 3Amikacin 3trifluridine tipiracil drug combination 2Piperacillin, Tazobactam Drug Combination 2Methylprednisolone 2Meropenem 2Irinotecan 2Etoposide 2Daptomycin 2Cisplatin 2Ceftazidime 2ziprasidone 1trilaciclib 1sargramostim 1niraparib 1liposomal amphotericin B 1lintuzumab 1leridistim 1isavuconazole 1fludarabine phosphate 1flt3 ligand protein 1fish oil triglycerides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neutropenia × ceftolozane, tazobactam drug combination × Clear all
NCT06422533 2024-06-04

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Instituto Nacional de Cancerologia de Mexico

Phase NA Recruiting
226 enrolled
Other hematologic neoplasm

Neutropenia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡